US Stock Insider Trading | ENvue Medical disclosed 30 insider transactions on February 4

2026-02-20 15:04:20

On February 4, 2026, ENvue Medical (FEED) disclosed 30 insider trading transactions. The shareholder owning more than 10%, BANK OF AMERICA CORP /DE/, sold 500 shares on February 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Shareholder >10%	BANK OF AMERICA CORP /DE/	February 2, 2026	Sell	100	3.04	304.00
February 4, 2026	Shareholder >10%	BANK OF AMERICA CORP /DE/	February 2, 2026	Sell	200	3.07	614.00
February 4, 2026	Shareholder >10%	BANK OF AMERICA CORP /DE/	February 2, 2026	Sell	300	3.06	918.00
February 4, 2026	Shareholder >10%	BANK OF AMERICA CORP /DE/	February 2, 2026	Sell	2,318	3.05	7,069.90
January 5, 2023	Director	MIKA THOMAS	January 5, 2023	Buy	50,000	0.25	12,500
June 17, 2022	Director	FASHEK CHRISTOPHER M	November 20, 2019	Buy	25,000	2.00	50,000
June 17, 2022	Director	FASHEK CHRISTOPHER M	June 15, 2022	Buy	40,000	0.60	23,800
June 14, 2022	Executive	BROWN STEPHEN RUSSELL	June 14, 2022	Buy	4,000	0.57	2,295.60
June 2, 2022	Director	Cassirer Aurora	June 1, 2022	Buy	2,000	0.69	1,380.00
October 9, 2020	Director	FASHEK CHRISTOPHER M	September 29, 2020	Buy	10,000	0.79	7,887.00

[Company Information]

ENvue Medical, Inc. was incorporated in Delaware on October 20, 2003. ENvue Medical operates through two wholly owned subsidiaries: NanoVibronix Ltd. in Israel and ENvue Medical Holdings LLC in Delaware. Nano OpCo focuses on developing non-invasive bioresponse activation devices that can be used at home without medical professional assistance to prevent biofilm formation, relieve pain, and promote wound healing. ENvue is a medical device company engaged in the research, development, manufacturing, marketing, and sales of medical devices in the enteral nutrition field.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes